6 Einträge gefunden

1. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis

   1. Gordon, K B
   2. Lebwohl, M
   3. Papp, K A
   4. Bachelez, H
   5. Wu, J J
   6. Langley, R G
   7. Blauvelt, A

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies

   1. Blauvelt, A
   2. Paul, C
   3. van de Kerkhof, P
   4. Warren, R B
   5. Gottlieb, A B
   6. Langley, R G
   7. Brock, F

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis

   1. Reich, K
   2. Mrowietz, U
   3. Menter, A
   4. Griffiths, C E M
   5. Bagel, J
   6. Strober, B
   7. Nunez Gomez, N

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial

   1. Warren, R B
   2. Lebwohl, M
   3. Sofen, H
   4. Piguet, V
   5. Augustin, M
   6. Brock, F
   7. C Arendt,

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Continued treatment with secukinumab is associated with high retention or regain of response

   1. Augustin, M
   2. Thaci, D
   3. Eyerich, K
   4. Pinter, A
   5. Radtke, M
   6. Lauffer, F
   7. Mrowietz, U

   2020 - Forschungsinformationssystem des UKE
6. Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis

   1. Lebwohl, M
   2. Langley, R G
   3. Zhu, Y
   4. Zhou, H
   5. Song, M
   6. Shen, Y K
   7. Parnell Lafferty, K

   2019 - Forschungsinformationssystem des UKE